A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

October 12, 2026

Study Completion Date

October 12, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

CC-92480

Specified dose on specified days

DRUG

Tazemetostat

Specified dose on specified days

DRUG

BMS-986158

Specified dose on specified days

DRUG

Trametinib

Specified dose on specified days

DRUG

Dexamethasone

Specified dose on specified days

Trial Locations (17)

10021

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

21287

RECRUITING

Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

35249

RECRUITING

UAB Comprehensive Cancer Center, Birmingham

39008

RECRUITING

Hospital Universitario Marques de Valdecilla, Santander

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

07601

RECRUITING

John Theurer Cancer Center at Hackensack UMC, Hackensack

T2N 5G2

RECRUITING

Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary

T6G 1Z2

RECRUITING

University of Alberta - Cross Cancer Institute, Edmonton

M5G 2M9

RECRUITING

University Health Network UHN - Princess Margaret Hospital PMH, Toronto

0450

RECRUITING

Oslo University Hospital, Oslo

08026

RECRUITING

ICO - Hospital Germans Trias i Pujol, Barcelona

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

LE1 5WW

WITHDRAWN

Local Institution - 0001, Leicester

L7 8YA

WITHDRAWN

Local Institution - 0014, Liverpool

OX3 7LE

RECRUITING

Churchill Hospital, Oxford

W1T 7HA

RECRUITING

NIHR UCLH Clinical Research Facility, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05372354 - A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter